drugset / Trial / NCT00495326

Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146 CARINEMO)

NCT00495326

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether the use of Nevirapine in HIV patients already treated against tuberculosis by Rifampicin is as efficient and as well tolerated as Efavirenz.

Timeline

Start
2007-12
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Efavirenz Other / unclassified 600 mg
Subject Nevirapine Small molecule 200 mg
Background Ethambutol Small molecule
Background Isoniazid Small molecule 5 mg/kg
Comparator Lamivudine Other / unclassified 150 mg
Comparator Lamivudine Other / unclassified 300 mg
Background Pyrazinamid Unknown
Background Rifampin Small molecule 10 mg/kg
Comparator Stavudine Other / unclassified 30 mg
Comparator Stavudine Other / unclassified 40 mg
Background streptomycin Other / unclassified

Indications